Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium gluconate monohydrate, quantity: 931 mg - injection, solution - excipient ingredients: calcium saccharate; water for injections - calcium gluconate is a calcium salt used primarily for the prevention and treatment of calcium deficiency. parenteral administation of calcium gluconate is needed in acute hypocalcaemia and hypocalcsemic tetany. it can be given intravenously in the treatment of severe hyper-kalaemia and in overdosage of magnesium sulphate, as calcium is the antagonist of magnesium toxicity. iv injections have been used in the treatment of acute renal biliary and intestinal colic. calcium has been used as an inotrope in cardiac resuscitation. they may also be used for the prevention of hypocalcaemia in exchange transfusions, and in long term electrolyte replacement therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - calcium chloride dihydrate 100 mg/ml; calcium chloride dihydrate 100 mg/ml - solution for injection - 1000 mg/10ml - active: calcium chloride dihydrate 100 mg/ml calcium chloride dihydrate 100 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - parenteral administration of calcium is indicated in the treatment of hypocalcaemia where a rapid increase in plasma calcium is required, such as in hypocalcaemic tetany and tetany due to parathyroid deficiency.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 10% - solution for infusion - 10 % - active: glucose monohydrate 10% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 25% - solution for infusion - 25 % - active: glucose monohydrate 25% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 5% - solution for infusion - 5 % - active: glucose monohydrate 5% - isotonic (glucose 5%) infusion solutions are mainly indicated for: - whenever non-electrolyte fluid replacement is required, - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 50% - solution for infusion - 50 % - active: glucose monohydrate 50% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 70% - solution for infusion - 70 % - active: glucose monohydrate 70% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - calcium carbonate - oral tablet - 250mg

United States - English - NLM (National Library of Medicine)

fresenius medical care north america - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698) - delflex® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis. none. risk summary delflex solutions consist of electrolytes, lactate, and bicarbonate at physiological levels, and glucose to facilitate ultrafiltration. while there are no adequate and well controlled studies in pregnant women, appropriate administration of delflex with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with delflex. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary the components of delflex solutions are excreted in human milk. appropriat

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - calcium folinate - solution for injection - calcium folinate 10 mg/ml - all other therapeutic products